Is FDA-Approved Psilocybin Coming? What It Means If You’re Considering Oregon

Possibly, in 2027. Compass Pathways, a drug company, is asking the FDA to approve its psilocybin product, COMP360, for treatment-resistant depression. COMP360 is synthetic psilocybin, made in a lab rather than grown. Nothing about psilocybin services in Oregon changes today, and you don’t have to wait for a federal decision to ask whether this is right for you.

What’s happening

Compass completed two large Phase 3 trials of COMP360 this year, and both hit their primary endpoint. The first, COMP005, tested a single 25-mg dose against a near-placebo control in 258 people and found a statistically significant drop in depression scores at six weeks. The second, COMP006, tested two 25-mg doses given three weeks apart in a larger group, with a similar-sized improvement that showed up the day after the first dose. COMP360 already holds FDA Breakthrough Therapy designation, and in April the FDA agreed to review Compass’s application on a rolling basis, meaning sections can be submitted as they’re finished instead of all at once. Compass also holds a Commissioner’s National Priority Voucher, which it says could shorten the FDA’s final review to one or two months once the full filing is in. The company is targeting a completed filing by the end of this year and a possible U.S. launch in the first half of 2027, assuming approval and the federal and state rescheduling that would have to follow it.

Those are Compass’s own numbers. Both trials are company-sponsored and company-reported, and the full datasets haven’t been published in a peer-reviewed journal yet. The one independent check so far is reassuring on safety: the trials’ monitoring board found no new or unexpected safety signals, and serious adverse events were uncommon in both studies.

What it would probably look like

Analysts who follow the filing expect two initial doses at least three weeks apart, with more at a clinician’s discretion, and about six hours of monitoring at each one. The first approved use would be treatment-resistant depression, not depression broadly. Clinically, that means major depressive disorder that hasn’t adequately responded to at least two different antidepressant medications, each tried at a full dose for a full course, within the current episode. Compass estimates that roughly 4 million people in the U.S. meet that bar.

On price, analysts tracking Compass’s September investor comments estimate a year of COMP360 could cost about what a year of the nasal spray Spravato costs: roughly $50,000 to $65,000, charged per dose. At two to four doses a year, that works out to around $16,700 to $21,700 per dose. That’s an outside estimate, not a number Compass has published or a list price, and how insurers will cover it is unknown. Permanent billing codes for this kind of treatment don’t exist yet.

What doesn’t change

Oregon’s licensed service centers are open today. In Oregon you’re 21 or older, you don’t need a diagnosis, and you don’t need a referral. Our price is $2,800, published, and it includes everything.

Screening comes first either way. A registered nurse reviews your medications and health history before anything is scheduled, and we’ll tell you honestly if the answer is “not yet.”

How to think about it

These are different things, and it helps to see them separately.

• An FDA-approved product would be a prescribed medicine, synthetic psilocybin, for a specific condition, given in a clinic under federal rules. When it arrives, who qualifies and who pays will depend on the label and on insurers.
• Oregon’s program is regulated at the state level and uses psilocybin mushrooms and products from state-licensed growers and manufacturers. It’s open to adults without a diagnosis, with preparation and integration built in.

Neither one is the right choice for everyone, and we’re not going to tell you ours is better. We’d rather you have the facts. If you’re weighing a wait for FDA approval against doing this now, that’s a real decision and it’s yours to make.

If you’d like to talk it through, start the conversation. Our Pricing page has the full cost, and our Sessions page explains what to expect. A real person reads every message.

Sources

• Compass Pathways. Second Quarter and First Half 2026 Financial Results and Business Highlights. Company press release, 2026.
• MoreBlossom. Psilocybin pricing signal: what Compass’s expected pricing implies for providers and payers. October 2026. (Reports Compass’s September investor statements.)